Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Nasdaq Biotechnology Ishares ETF (NQ: IBB)
120.55 USD  -0.17 (-0.14%)
Official Closing Price  /  Updated: 4:39 PM EST, Jan 22, 2020  /  Add to My Watchlist      
View: Quote News
Fund Overview
Nasdaq Biotechnology Ishares ETF
Sector
Exchange Traded NQ
Net Assets 10.48B
Inception Date
Related Funds
Quote
Price 120.55
Volume 1,395,434
Last Trade Jan 22, 4:39pm
Change (%)
-0.17 (-0.14%)
Prev. Close 120.72
YTD %
+0.55%
Dividend Yield 0.26%
Performance
YTD
+0.66 (0.55%)
1 Month
-2.37 (-1.93%)
3 Month
+14.91 (14.11%)
6 Month
+14.87 (14.07%)
1 Year
+11.83 (10.88%)
Chart
Charting
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... Read More
from Benzinga
How’s The Market’s Appetite For Risk?
With Nasdaq 100 making yet another new all-time high early on while closing lower, has this rally now turned into the world of expensive junk? Read More
from Blogs - TalkMarkets
Top News
More News
7 Blockbuster Drugs Expected To Be Launched In 2020
Biotech stocks had a fairly decent run in 2019, thanks to record deal flow, several path-breaking innovation in drug research & ... Read More
from Benzinga
The Week Ahead In Biotech: Focus On Epizyme, Merck Ahead Of PDUFA Dates, J&J To Kickstart Big Pharma Earnings
Biotech news flow remained light last week, although there were some notable developments such as FDA panel reviews of opioid pain ... Read More
from Benzinga
3 Top Biotech Picks for 2020
These stocks could thump the broader markets this year. Read More
from Motley Fool
Biotechnology Stocks About To Take Off
The biotechnology sector is working hard, very hard. It is attempting to take off. It has to overcome 4.5-year horizontal resistance. Read More
from Blogs - TalkMarkets
Investors: Get Ready For The Year Of The Metal Rat
Natural disasters could impact the prices of raw materials, still trading at historical lows compared to equities. What else might we prepare for as the year continues? There could be a continuation of... Read More
from Blogs - TalkMarkets
9 Takeaways From The JPMorgan Healthcare Conference
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights ... Read More
from Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that ... Read More
from Benzinga
The Math Shows IBB Can Go To $145
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... Read More
from ETF Channel
5 Reasons 2020 Will Be a Big Year for Ionis Pharmaceuticals
Investors are overly focused on one issue with this stock while the company is making progress on many fronts. Read More
from Motley Fool
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... Read More
from Benzinga
Why Regional Banks KRE Is The Prodigal Son
Today, for the first time since October 2019, KRE broke below the 50-daily moving average. Read More
from Blogs - TalkMarkets
The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that ... Read More
from Benzinga
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that ... Read More
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.